1. Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
   Jiangping Yang et al, 2021, Frontiers in Oncology CrossRef
2. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer
   Yin Min Thu et al, 2024, PLOS ONE CrossRef
3. Novel 3D Liquid Cell Culture Method for Anchorage-independent Cell Growth, Cell Imaging and Automated Drug Screening
   Natsuki Abe-Fukasawa et al, 2018, Scientific Reports CrossRef
4. IL‐17A promotes cell migration and invasion of glioblastoma cells via activation of PI3K/AKT signalling pathway
   Qianqian Zheng et al, 2019, Journal of Cellular and Molecular Medicine CrossRef
5. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
   Elona Cekani et al, 2022, Cancers CrossRef
6. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1
   Xiaoqiang Zhang et al, 2017, Biomedicine & Pharmacotherapy CrossRef
7. Systematic analysis of the transcriptional landscape of melanoma reveals drug-target expression plasticity
   Brad Balderson et al, 2024, Briefings in Functional Genomics CrossRef
8. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors
   Jiawan Wang et al, 2021, Cancer Research CrossRef
9. βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells
   Simon Brayford et al, 2023, Cancer Medicine CrossRef
10. Integrating metabolomics and network toxicology to reveal the mechanism of hypoaconitine-induced hepatotoxicity in mice
    Yihui Yin et al, 2024, Pesticide Biochemistry and Physiology CrossRef
11. Targeting MEK in non-small cell lung cancer
    Matthew S. Lara et al, 2024, Current Problems in Cancer CrossRef
12. Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management
    Smriti Dhingra et al, 2024, Nanomedicine CrossRef
13. Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma
    Qinglian Chen et al, 2021, Hepatology Research CrossRef
14. Reference Size Matching, Whole-Genome Amplification, and Fluorescent Labeling as a Method for Chromosomal Microarray Analysis of Clinically Actionable Copy Number Alterations in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
    Shelly R. Gunn et al, 2018, The Journal of Molecular Diagnostics CrossRef
15. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
    Maristella Bungaro et al, 2022, Current Treatment Options in Oncology CrossRef
16. Nanoscale Mapping of EGFR and c-MET Protein Environments on Lung Cancer Cell Surfaces via Therapeutic Antibody Photocatalyst Conjugates
    Tamara Reyes-Robles et al, 2022, ACS Chemical Biology CrossRef
17. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies
    Qing-Ge Zhu et al, 2017, Oncotarget CrossRef
18. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression
    Nobuhiro Kanaji et al, 2017, Respiratory Research CrossRef
19. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
    Morana Vojnic et al, 2019, Journal of Thoracic Oncology CrossRef
20. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
    Anne-Laure Désage et al, 2022, Frontiers in Oncology CrossRef